Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xembify versus Gamunex-C pharmacokinetics and safety study in adults with CIDP
2025-522165-30-00Phase 3Authorised
- Sponsor
- Grifols
- Start
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of polyvalent human immunoglobulin and immune globulin in chronic inflammatory demyelinating polyneuropathy (CIDP) (2 arms), sponsored by Grifols. Primary endpoints: AUC in the IV Phase and AUC in the SC Phase. Planned start Jul 2026; status: authorised.
02
Drugs
polyvalent human immunoglobulinimmune globulin
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on 2025-522165-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522165-30-00.